Britain’s drug regulator announced Monday that it has approved a new generation of Moderna’s COVID-19 vaccine targeting the Omicron variant, a world first according to the lab.
• Read also: Shortage of pharmacists causes sometimes fatal prescription errors
• Read also: Rise in requests for help as the new school year approaches
• Read also: Small miracles of medicine: healthier premature babies
This version of the vaccine consists of a so-called “bivalent” booster dose, targeting half the original strain of the virus and half the Omicron variant and “provokes a strong immune response” against both, including against the subvariants of Omicron BA.4 and BA.5, the MHRA said in a statement.
It “has been approved for booster doses for adults by the MHRA which concluded that it meets the safety, quality and efficacy standards of the British regulator”, added the drug agency.
The side effects observed are “typically weak” and similar to those observed for the original serums, it is specified.
“What this bivalent vaccine gives us is a sharper tool in our toolbox to help protect us against this disease as the virus continues to evolve,” MHRA Director June Raine said. in a press release.
The director general of Moderna Stéphane Bancel underlined for his part “the important role” that this “new generation” of vaccine can play in the protection against Covid-19.
He noted that the United Kingdom thus became the first country to approve a bivalent vaccine partly targeting Omicron, the variant that has become the most widespread in Europe.
Last week, the European Medicines Agency (EMA) said it was aiming for approval as early as the fall of a Pfizer/BioNTech COVID-19 vaccine targeting two subvariants of the rapidly spreading Omicron strain, BA.4 and BA.5.
While vaccinations have helped reduce hospitalizations and deaths from COVID-19, which first emerged in China in late 2019, current injections mainly target earlier strains of the disease.
The World Health Organization (WHO) warned in July that the pandemic was “far from over”, due to the spread of Omicron sub-variants, the lifting of health restrictions and the drop in testing. .
COVID-19 cases spiked globally in late spring and early summer, driven by newer variants, but have since started to level off in Europe.
European countries are now starting to look to autumn and winter, when cases are expected to rise again.
The United Kingdom is one of the countries most affected in Europe by the pandemic with nearly 180,000 deaths. While mortality has fallen sharply thanks to vaccination, the country regularly experiences large waves of contamination, but was one of the first in Europe to lift all restrictions last winter.